Literature DB >> 8525428

Gene targeting in mouse embryonic stem cells with an adenoviral vector.

K Mitani1, M Wakamiya, P Hasty, F L Graham, A Bradley, C T Caskey.   

Abstract

We examined the ability of an E1, E3-defective adenoviral vector to act as a substrate for homologous recombination with chromosomal DNA by including host chromosomal sequence from the mouse Fgr locus that also contained a selectable marker. After infection of mouse embryonic stem cells, stable integration was selected for neomycin resistance and the efficiency of homologous recombination was evaluated. The adenoviral vector was capable of infecting mouse embryonic stem cells efficiently. Between 30-50% of the input virus reached the nuclei after 24 hours of infection. Surprisingly, even without negative selection, 25-40% of the integration resulted from homologous recombination at m.o.i. 10 and 100, although the absolute efficiency of integration was low. Our results suggest that it is possible to modify the structure of an adenoviral vector to achieve a high gene targeting efficiency, resulting in regulated and long-term expression of an introduced gene.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8525428     DOI: 10.1007/bf02255777

Source DB:  PubMed          Journal:  Somat Cell Mol Genet        ISSN: 0740-7750


  9 in total

1.  Chromosomal integration pattern of a helper-dependent minimal adenovirus vector with a selectable marker inserted into a 27.4-kilobase genomic stuffer.

Authors:  M Hillgenberg; H Tönnies; M Strauss
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 2.  Current strategies and future directions for eluding adenoviral vector immunity.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2006-04       Impact factor: 4.391

Review 3.  Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances.

Authors:  Guy L Odom; Paul Gregorevic; Jeffrey S Chamberlain
Journal:  Biochim Biophys Acta       Date:  2006-09-26

4.  Correction of chromosomal mutation and random integration in embryonic stem cells with helper-dependent adenoviral vectors.

Authors:  Fumi Ohbayashi; Michael A Balamotis; Atsuhiro Kishimoto; Emi Aizawa; Arturo Diaz; Paul Hasty; Frank L Graham; C Thomas Caskey; Kohnosuke Mitani
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-07       Impact factor: 11.205

Review 5.  Gene therapy for type I glycogen storage diseases.

Authors:  Janice Y Chou; Brian C Mansfield
Journal:  Curr Gene Ther       Date:  2007-04       Impact factor: 4.391

6.  Glucose-6-phosphate transporter gene therapy corrects metabolic and myeloid abnormalities in glycogen storage disease type Ib mice.

Authors:  W H Yiu; C-J Pan; M Allamarvdasht; S Y Kim; J Y Chou
Journal:  Gene Ther       Date:  2006-09-28       Impact factor: 5.250

7.  Human gene targeting by viral vectors.

Authors:  D W Russell; R K Hirata
Journal:  Nat Genet       Date:  1998-04       Impact factor: 38.330

8.  A trial of somatic gene targeting in vivo with an adenovirus vector.

Authors:  Asami Ino; Yasuhiro Naito; Hiroyuki Mizuguchi; Naofumi Handa; Takao Hayakawa; Ichizo Kobayashi
Journal:  Genet Vaccines Ther       Date:  2005-10-12

9.  Gene transfer into mouse embryonic stem cell-derived cardiac myocytes mediated by recombinant adenovirus.

Authors:  E M Rust; M V Westfall; L C Samuelson; J M Metzger
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-04       Impact factor: 2.723

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.